Japan shares look to snap six-day losing streak
Japan's benchmark stock-market index pushed higher on Wednesday as traders there got a chance to react to China's rate cut.
Published by Capital Market Laboratories on 2015-08-13 8:49 P.M.
( GPRO )
Golden Cross Alert: The 50-day MA is now above the 200-day MA.
Swing Golden Cross Alert: The short-term 10 day MA is now above the 50 day MA.
GPRO has a four bull (high rated) technical rating because it's trading above both its 50- and 200-day moving averages.
With all the stocks to short why would anyone want to short a #1 buyout target,, babbles me. Anyone post to Stocktwits yet?
basher? Seris of international launches is a great thing
Analysts Confident in Fitbit Inc’s (FIT) Ability to Dominate Fitness Wearables Market
By Cody Miecnikowski
The company has continued to show momentum along with brand leadership, an expanding product line, and growing sales. Fitbit is on track to grow and penetrate a large share of the global fitness market. In regards to paid services, “Fitbit’s longer-term aspiration is to drive additional revenue streams from software and services fees, capitalizing on its device and app. customer base. To this end, it recently acquired FitStar to enhance its online software capabilities. This is also a major focus of its current R&D efforts. The global fitness market exceeds $200 billion annually, signifying a huge opportunity for the company. The healthier lifestyle change we’re seeing in the US is being mirrored overseas and international contributes about 25% of sales, offering substantive growth opportunities.”
Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company Says
Needham & Company analyst Chad Messer reiterated a Buy rating and $130 price target on Esperion Therapeutics (NASDAQ: ESPR) following a read-through from Alirocumab AdComm, which they view as a net positive for ETC-1002.